BioMarin Pharmaceuticals
BMRN
537 hedge funds and large institutions have $16.1B invested in BioMarin Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 98 funds opening new positions, 195 increasing their positions, 172 reducing their positions, and 53 closing their positions.
85% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 53
29% more call options, than puts
Call options by funds: $319M | Put options by funds: $247M
18% more capital invested
Capital invested by funds: $13.6B → $16.1B (+$2.51B)
13% more repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 172
8% more funds holding
Funds holding: 496 → 537 (+41)
1.66% more ownership
Funds ownership: 98.96% → 100.62% (+1.7%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$165M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$107M |
| 3 |
Parnassus Investments
San Francisco,
California
|
+$106M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$78.7M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$64.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$58.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$46.7M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$46.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$44.6M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$42.2M |
BMRN Hedge Fund Activity: Q4 2020 in Review
537 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2020, worth a combined $16.1B — up 18% from $13.6B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new BMRN positions and 53 closed out — a net gain of 45 holders — while 195 added to existing stakes and 172 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $165M. The largest seller was JP Morgan Chase, cutting an estimated $58.5M.
- 537 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2020, up from 496 in Q3 2020.
- Funds reported $16.1B of BioMarin Pharmaceuticals stock for Q4 2020, up 18% quarter-over-quarter.
- 98 funds opened new BioMarin Pharmaceuticals positions in Q4 2020 and 53 closed out, a net change of +45 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2020 was Dodge & Cox, an estimated $165M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2020 was JP Morgan Chase, an estimated $58.5M sold.
Based on aggregated 13F filings for Q4 2020.